Definition, classification, and adjacent boundaries
Theanine ingredients are food or formulation materials standardized for theanine, ordinarily the naturally occurring L-enantiomer L-theanine, also known as gamma-glutamylethylamide. They may be produced by extraction from tea, chemical synthesis, enzyme catalysis, or microbial manufacture. In the WSIC, this entry is coded 6.1.1 under Industry Support / R&D, Manufacturing and Supply Chain / Specialized Components and Materials. Theanine is a non-protein amino acid for which tea plants are an important natural source, but natural occurrence does not establish that every source, purity, use, or claim has the same safety or evidentiary status.
A specification using the name “theanine” should state whether it covers the L-enantiomer, the D-enantiomer, or a racemic mixture, as well as the assay basis, manufacturing route, and any carrier. Highly purified L-theanine, decaffeinated tea extract, ordinary tea powder, and a tea-containing beverage are not interchangeable. The latter materials may also contain caffeine, catechins, polyphenols, and aroma compounds. Because caffeine can delay sleep and shorten sleep duration, results from caffeinated tea or combination products do not directly establish the sleep effect of pure L-theanine.
An ingredient is also distinct from a finished product or a treatment program. Conforming ingredient results do not establish serving-level content, stability, safety, or clinical performance in capsules, gummies, beverages, or multi-ingredient products. Theanine is not the same substance as gamma-aminobutyric acid, glutamine, glutamate, tea polyphenols, or sedative-hypnotic medicines. This entry addresses ingredient identity, manufacture, and evidence boundaries; it does not provide personal dosing, timing, or insomnia-treatment advice.
Source routes, stereochemistry, and material identity
A tea-extraction route should trace the Camellia species, plant part, origin, harvest season, tea-making or pretreatment conditions, extraction solvent, decaffeination step, concentration ratio, and excipients. Free-amino-acid composition in fresh leaves and processed tea changes with cultivar, cultivation, shading, harvest, and processing, so “from green tea” is not a sufficient batch definition. Extract specifications should also control caffeine, catechins, pigments, pesticides, mycotoxins, elemental impurities, and microorganisms, and should make clear whether the material is purified theanine or a multicomponent standardized extract.
Chemical synthesis can yield a highly purified product, but a route may leave unreacted glutamate, ethylamine or their derivatives, positional or structurally related substances, reagents, catalysts, and solvents, and may generate D-theanine or racemization. Enzymatic synthesis commonly uses a catalyst such as gamma-glutamyl transpeptidase to form the L-configuration. Microbial or whole-cell routes additionally require control of the production organism, genetic construct, cell bank, medium, and downstream removal. Depending on process risk, biological production should address viable cells, host-cell protein, DNA, endotoxin, and other cellular residues.
Material identity is therefore a combination of chemical structure, L/D configuration, assay, source route, and relevant solid-state or physical properties. “Natural,” “fermented,” and “enzymatic” are not quality grades and do not replace impurity evaluation. Stable-isotope ratios can support an origin-authenticity investigation, but raw materials, culture substrates, and processing can all affect the signature. Isotope data cannot by themselves replace chromatographic identity, enantiomeric purity, and complete supply-chain records.
Extraction, synthesis, and process control
A tea route may include extraction with water or another permitted solvent, solid-liquid separation, decolorization, decaffeination, membrane separation, adsorption or ion exchange, concentration, crystallization, and drying. Critical parameters should be linked to theanine recovery and impurity clearance, with particular evidence that caffeine, catechins, pesticide residues, and colored matter are not concentrated into the output. Changes to resin, membranes, activated carbon, or solvents can alter selectivity and extractables. Mother-liquor reuse and reprocessing need predefined limits, material balance, and deviation review.
Chemical and enzymatic manufacture should control input identity and stoichiometry, pH, temperature, reaction time, enzyme activity or catalytic conditions, endpoint, extraction, desalting, crystallization, and drying. Reaction completion should not be inferred from total nitrogen or total amino acids alone; the target, remaining substrates, and important by-products should be observed separately. Microbial manufacture also needs controls for strain identity and stability, adventitious contamination, substrate use, pathway by-products, and cell removal. A change in organism, enzyme, medium, or substrate origin can change both the impurity profile and regulatory identity.
Post-purification crystallization, milling, sieving, and blending can affect solid form, particle size, bulk density, flow, moisture uptake, and blend uniformity in the finished product. Critical intermediates and the final ingredient require controlled hold time, temperature, humidity, and cross-contamination prevention. Process capability should be demonstrated with multiple batches and atypical trends, deviations, or out-of-specification results should receive root-cause investigation. An abnormal lot must not be diluted with a high-purity lot, and a passing final assay must not conceal a loss of upstream process control.
Analysis, specification, and batch release
Identity and assay can be determined with a validated HPLC or UPLC method and supported by orthogonal tools such as mass spectrometry, infrared spectroscopy, nuclear magnetic resonance, or amino-acid analysis. In a tea matrix, the method should demonstrate separation from other free amino acids, glutamyl derivatives, and co-extractives. GB/T 23193-2017 provides an HPLC framework for theanine in tea, but each ingredient and finished-product matrix still requires validation of specificity, recovery, precision, accuracy, quantitation limit, and solution stability. Total amino acids, total nitrogen, or a nonspecific color reaction is not a substitute for theanine assay.
If the label or specification identifies L-theanine, a single main peak on an achiral chromatogram does not exclude the D-isomer. A suitable chiral separation or another stereospecific method is needed. A release specification commonly includes appearance, identity, assay on a stated dry or as-is basis, enantiomeric purity, related substances, water or loss on drying, residual solvents, elemental impurities, ash, and microbiological quality. Tea-derived material additionally calls for caffeine, catechins, pesticide, and mycotoxin controls, while fermentation-derived material needs relevant biological-process residuals.
A certificate of analysis should report the actual lot number, manufacturing and retest dates, method versions, and numerical results rather than only “complies.” Reference standards need assigned values, purity correction, and storage conditions. Method transfer must address column type, derivatization, detector response, and matrix differences. The finished-product manufacturer must also validate representative sampling, content uniformity at a low inclusion rate, and process recovery. A conforming ingredient test does not show that every gummy, drink-powder serving, or capsule meets its label amount.
Formulation stability, exposure, and safety
A stability program should cover temperature, humidity, light, oxygen, packaging, and realistic transport while following assay, degradants, moisture, color, and physical condition. Theanine has a free amino group and can participate in browning chemistry in heated systems containing reducing sugars. Beverage pH and pasteurization, gummy cooking temperature, and moisture-driven caking of powders may therefore change recovery. Ingredient data cannot substitute for a shelf-life study of the final formulation; stability-indicating methods and the actual package should be used where appropriate.
Safety evaluation should be tied to a defined ingredient, use, total daily exposure, and population. It should not be extrapolated indefinitely from one supplier or manufacturing route. Published human studies are generally limited in size and duration. Reported complaints can include headache, gastrointestinal discomfort, drowsiness, or blood-pressure changes, although findings are not uniform across materials and studies. Co-exposure to caffeine, alcohol, sedating ingredients, or medicines that affect blood pressure may change the risk assessment. Pregnancy and lactation, children, chronic disease, and concurrent medication require separate evidence and professional review.
Risk management must also consider stacking across products: tea, energy or functional beverages, and sleep blends can contribute both theanine and caffeine. Labels should accurately state active and relevant accompanying constituents. “Caffeine free” should not obscure a measurable residual, and “relaxation” should not be presented as inevitable sedation. Complaints, excessive use, interaction signals, and adverse events should be investigated by lot, formulation, and co-exposure, then fed back into specification, labeling, and supplier controls.
Human evidence and boundaries of sleep claims
Human trials and systematic reviews suggest that L-theanine may improve some subjective sleep outcomes, but results depend on sample size, duration, dosage form, baseline condition, and endpoint selection. A 2025 systematic review of sleep studies found improvement in several subjective measures while specifically noting the shortage of research on pure L-theanine and uncertainty over dose and duration. Evidence for objective sleep architecture, daytime function, and durable benefit is more limited. A research signal is therefore not the same as an established treatment effect.
Attribution requires separation of pure L-theanine from caffeinated tea, theanine-caffeine combinations, and blends containing GABA, magnesium, casein hydrolysate, or other ingredients. A favorable combination trial cannot identify theanine as the cause. Results in selected groups such as cancer patients, people under stress, or participants with short-term sleep complaints also cannot be transferred without qualification to the general population or chronic insomnia. A marketed product should match the source, purity, stereochemistry, amount, and co-ingredients of the studied material rather than claim equivalence from the ingredient name alone.
A theanine ingredient should not be described as a medicine that diagnoses, prevents, or treats insomnia unless the specific product has obtained that authorization in the relevant jurisdiction. A sleep claim must fit reproducible human endpoints, the actual formulation, and legally permitted language, while explicitly handling caffeine as an opposing confounder. Persistent insomnia, marked daytime impairment, or suspected sleep-disordered breathing warrants clinical assessment. An ingredient or supplement does not replace cognitive behavioral therapy for insomnia or other evidence-based care.
Regulation, procurement, and continuing verification
Regulatory identity depends on jurisdiction, manufacturing route, specification, use, and population. China’s 2014 No. 15 announcement lists “tea-leaf theanine” with defined source, process, and conditions of use; it does not automatically cover chemically synthesized or microbial routes. Likewise, US FDA “no questions” responses to several L-theanine GRAS notices apply to the notifier’s described substance, manufacture, and intended uses. They are not blanket approvals of all theanine ingredients, and a notice still pending review must not be represented as accepted.
A purchasing agreement should lock the name and configuration, source route, manufacturing site, specification, analytical methods, reference standards, package, shelf life, and regulatory documentation, and require disclosure of important changes. Supplier qualification should examine tea supply, organism or enzyme, substrates, resins, solvents, reprocessing, cross-contamination, and data integrity. Initial and periodic independent testing should confirm identity, assay, enantiomeric purity, and route-specific impurities. Brand narratives, generic food certificates, and historical certificates of analysis do not replace lot control.
Change management should cover tea origin, decaffeination, synthetic route, strain and genetic construct, enzyme and medium, purification media, drying, particle size, carrier, methods, and package. The control strategy and claims should be periodically reviewed against stability trends, complaints, adverse events, regulatory changes, and new clinical evidence. Before a specification is widened, a supplier is changed, or capacity is scaled, comparability of ingredient identity, impurities, finished-product processing performance, and lawful use should be demonstrated.